サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：多嚢胞性卵巣症候群 (PCOS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析
市場調査レポート
商品コード
1182390

多嚢胞性卵巣症候群 (PCOS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析

Polycystic Ovarian Syndrome (PCOS) Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
多嚢胞性卵巣症候群 (PCOS) 治療薬の世界市場 (2022～2030年)：成長・将来の展望・競合分析
出版日: 2022年08月24日
発行: Acute Market Reports
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多嚢胞性卵巣症候群 (PCOS) 治療薬の市場は、有病率の増加、生活様式の変化、早期診断、重大なアンメットニーズなどの要因により、急速に拡大しています。

米国国立衛生研究所（NIH）によると、PCOSは、世界の出産年齢の女性の8～20％が罹患していると言われています。2020年には、北米地域がPCOS治療薬市場を独占しています。米国は、対象となる人口が多いこと、治療薬のコストが高いこと、ライフスタイルのパターン、一般住民の治療意識が高いことなどが理由で、最大の収益規模を示しています。

当レポートでは、世界の多嚢胞性卵巣症候群 (PCOS) 治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 多嚢胞性卵巣症候群 (PCOS) 治療薬市場：競合分析

  • ベンダーの市場における位置づけ
  • ベンダーの採用戦略
  • 主要産業戦略
  • ティア分析：2021年・2030年

第4章 多嚢胞性卵巣症候群 (PCOS) 治療薬市場：マクロ分析・市場力学

  • 世界市場の規模：2020-2030年
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析

第5章 多嚢胞性卵巣症候群 (PCOS) 治療薬市場：薬剤別

  • 市場概要
  • 成長・収益分析：2021年・2030年
  • 市場の分類
    • 経口避妊薬
    • 排卵誘発剤
    • フェイシャルヘア新生阻害剤
    • インスリン抵抗性改善剤
    • その他

第6章 北米の多嚢胞性卵巣症候群 (PCOS) 治療薬市場

  • 市場概要
  • PCOS治療薬市場：薬剤別
  • PCOS治療薬市場：地域別

第7章 英国およびEUの多嚢胞性卵巣症候群 (PCOS) 治療薬市場

  • 市場概要
  • PCOS治療薬市場：薬剤別
  • PCOS治療薬市場：地域別

第8章 アジア太平洋の多嚢胞性卵巣症候群 (PCOS) 治療薬市場

  • 市場概要
  • PCOS治療薬市場：薬剤別
  • PCOS治療薬市場：地域別

第9章 ラテンアメリカの多嚢胞性卵巣症候群 (PCOS) 治療薬市場

  • 市場概要
  • PCOS治療薬市場：薬剤別
  • PCOS治療薬市場：地域別

第10章 中東およびアフリカの多嚢胞性卵巣症候群 (PCOS) 治療薬市場

  • 市場概要
  • PCOS治療薬市場：薬剤別
  • PCOS治療薬市場：地域別

第11章 企業プロファイル

  • Bristol Myers Squibb
  • Crinetics Pharmaceuticals, Inc.
  • EffRx, Inc.
  • Ferring Pharmaceuticals
  • Merck KGaA
  • Neurocrine Biosciences, Inc.
  • Novartis Pharmaceuticals
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Limited
図表

List of Tables

  • TABLE 1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 3 U.S. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 4 Canada Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 7 UK Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 8 Germany Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 9 Spain Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 10 Italy Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 11 France Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 13 Asia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 14 China Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 15 Japan Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 16 India Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 17 Australia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 18 South Korea Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 19 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 20 Brazil Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 21 Mexico Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 24 GCC Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 25 Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Quality Assurance
  • FIG. 5 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Drug, 2021
  • FIG. 6 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2021
  • FIG. 8 Market Positioning of Key Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Players, 2021
  • FIG. 9 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Drug, 2021 Vs 2030, %
  • FIG. 11 U.S. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 18 France Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 20 China Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 22 India Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market (US$ Million), 2020 - 2030
目次
Product Code: 137764-08-22

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Polycystic ovarian syndrome (PCOS) therapeutics market is rapidly growing due to factors such as growing prevalence, changing lifestyle pattern, early diagnosis and significant unmet needs.

The report titled "Polycystic ovarian syndrome (PCOS) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall PCOS therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug type and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global polycystic ovarian syndrome (PCOS) therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global polycystic ovarian syndrome (PCOS) therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global polycystic ovarian syndrome (PCOS) therapeutics market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global polycystic ovarian syndrome (PCOS) therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.

Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting approximately 10 percent of women of reproductive age. Women with PCOS may have infrequent or menstrual periods or excess male hormone levels. There is no cure for PCOS but treatment focuses on managing symptoms, such as infertility, hirsutism, acne or obesity. Change in lifestyle, increase in prevalence of PCOS and rising treatment awareness are prime factors that drive the growth of PCOS therapeutics market globally. For the purpose of the study PCOS therapeutics market is segmented on the basis of drug type such as oral contraceptive, ovulation inducing agents, facial hair growth inhibitor, insulin sensitizing agent and other therapeutics. Currently, oral contraceptive is the major revenue contributor because it is preferred as first line treatment option. Oral contraceptives are effective to regulate PCOS symptoms such as reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the skin and to regulate the periods.

According to national institutes of health (NIH), PCOS affects 8 to 20 percent of reproductive age women worldwide. In the base year 2020, North America dominated the polycystic ovarian syndrome (PCOS) therapeutics market. United States was largest revenue contributor due to the higher number of targeted population, higher cost of therapeutics, lifestyle pattern and higher treatment awareness among the general population. According to national institutes of health (NIH), PCOS affects more than 5 percent of women in the United States. On the other hand, rapid evolution of healthcare infrastructure, increasing number of target population, growing treatment awareness among the general population and increasing penetration of major market players will lead to Asia Pacific witnessing the fastest growth rate.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Polycystic Ovarian Syndrome (PCOS) Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Polycystic Ovarian Syndrome (PCOS) Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

  • Oral Contraceptive
  • Ovulation Inducing Agents
  • Facial Hair Growth Inhibitor
  • Insulin Sensitizing Agent
  • Other Drugs

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Polycystic Ovarian Syndrome (PCOS) Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Polycystic Ovarian Syndrome (PCOS) Therapeutics market?
  • Which is the largest regional market for Polycystic Ovarian Syndrome (PCOS) Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Polycystic Ovarian Syndrome (PCOS) Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Polycystic Ovarian Syndrome (PCOS) Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
  • 2.2. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Oral Contraceptive
    • 5.3.2. Ovulation Inducing Agents
    • 5.3.3. Facial Hair Growth Inhibitor
    • 5.3.4. Insulin Sensitizing Agent
    • 5.3.5. Other Drugs

6. North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

7. UK and European Union Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

8. Asia Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

9. Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

10. Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
  • 10.3.Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: By Drug, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Bristol Myers Squibb
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Crinetics Pharmaceuticals, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. EffRx, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Ferring Pharmaceuticals
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Merck KGaA
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Neurocrine Biosciences, Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Novartis Pharmaceuticals
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Pfizer Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Sanofi Aventis
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Teva Pharmaceutical Industries Limited
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives